Evgen Pharma plc
(“Evgen” or the “Company”)
Share price movement
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company focused on the treatment of cancer and neurological conditions, notes the increase in the Company’s share price in recent days.
Evgen can confirm that it is in discussions with a potential source of funds that would help pay for a clinical trial in Covid-19 patients, with Evgen providing SFX-01 in support of such a trial.
A further announcement will be made if these discussions are successful.
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
Evgen Pharma plc www.evgen.com
Barry Clare, Chairman
Richard Moulson, CFO
+44 (0)20 7220 0500
Geoff Nash / Teddy Whiley (Corporate Finance)
Alice Lane / Manasa Patil (ECM)
+44 (0)20 7933 87870 or [email protected]
Paul McManus / Anna Dunphy
+44 (0)7980 541 893 / +44 (0)7876 741 001
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company’s core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company’s open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.
The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com